Literature DB >> 30869655

Anti-Neurofascin-155 IgG4 antibodies prevent paranodal complex formation in vivo.

Constance Manso1,2, Luis Querol3,4, Cinta Lleixà3,4, Mallory Poncelet5, Mourad Mekaouche1,6, Jean-Michel Vallat7, Isabel Illa3,4, Jérôme J Devaux1,5.   

Abstract

Neurofascin-155 (Nfasc155) is an essential glial cell adhesion molecule expressed in paranodal septate-like junctions of peripheral and central myelinated axons. The genetic deletion of Nfasc155 results in the loss of septate-like junctions and in conduction slowing. In humans, IgG4 antibodies against Nfasc155 are implicated in the pathogenesis of chronic inflammatory demyelinating polyneuropathy (CIDP). These antibodies are associated with an aggressive onset, a refractoriness to intravenous immunoglobulin, and tremor of possible cerebellar origin. Here, we examined the pathogenic effects of patient-derived anti-Nfasc155 IgG4. These antibodies did not inhibit the ability of Nfasc155 to complex with its axonal partners contactin-1/CASPR1 or induce target internalization. Passive transfer experiments revealed that IgG4 antibodies target Nfasc155 on Schwann cell surface, and diminished Nfasc155 protein levels and prevented paranodal complex formation in neonatal animals. In adult animals, chronic intrathecal infusions of antibodies also induced the loss of Nfasc155 and of paranodal specialization and resulted in conduction alterations in motor nerves. These results indicate that anti-Nfasc155 IgG4 perturb conduction in absence of demyelination, validating the existence of paranodopathy. These results also shed light on the mechanisms regulating protein insertion at paranodes.

Entities:  

Keywords:  Autoimmune diseases; Autoimmunity; Neurological disorders; Neuromuscular disease; Neuroscience

Year:  2019        PMID: 30869655      PMCID: PMC6546478          DOI: 10.1172/JCI124694

Source DB:  PubMed          Journal:  J Clin Invest        ISSN: 0021-9738            Impact factor:   14.808


  52 in total

1.  Contactin orchestrates assembly of the septate-like junctions at the paranode in myelinated peripheral nerve.

Authors:  M E Boyle; E O Berglund; K K Murai; L Weber; E Peles; B Ranscht
Journal:  Neuron       Date:  2001-05       Impact factor: 17.173

2.  In vivo deletion of immunoglobulin domains 5 and 6 in neurofascin (Nfasc) reveals domain-specific requirements in myelinated axons.

Authors:  Courtney Thaxton; Anilkumar M Pillai; Alaine L Pribisko; Marilyne Labasque; Jeffrey L Dupree; Catherine Faivre-Sarrailh; Manzoor A Bhat
Journal:  J Neurosci       Date:  2010-04-07       Impact factor: 6.167

3.  CNS myelin paranodes require Nkx6-2 homeoprotein transcriptional activity for normal structure.

Authors:  Cherie Southwood; Chris He; James Garbern; John Kamholz; Edgardo Arroyo; Alexander Gow
Journal:  J Neurosci       Date:  2004-12-15       Impact factor: 6.167

4.  Antibodies to neurofascin exacerbate adoptive transfer experimental autoimmune neuritis.

Authors:  Weixing Yan; Toan Nguyen; Nobuhiro Yuki; Qiuhong Ji; Con Yiannikas; John D Pollard; Emily K Mathey
Journal:  J Neuroimmunol       Date:  2014-09-18       Impact factor: 3.478

5.  Long-term maintenance of Na+ channels at nodes of Ranvier depends on glial contact mediated by gliomedin and NrCAM.

Authors:  Veronique Amor; Konstantin Feinberg; Yael Eshed-Eisenbach; Anya Vainshtein; Shahar Frechter; Martin Grumet; Jack Rosenbluth; Elior Peles
Journal:  J Neurosci       Date:  2014-04-09       Impact factor: 6.167

6.  Specific contactin N-glycans are implicated in neurofascin binding and autoimmune targeting in peripheral neuropathies.

Authors:  Marilyne Labasque; Bruno Hivert; Gisela Nogales-Gadea; Luis Querol; Isabel Illa; Catherine Faivre-Sarrailh
Journal:  J Biol Chem       Date:  2014-02-04       Impact factor: 5.157

7.  Postnatal Loss of Neuronal and Glial Neurofascins Differentially Affects Node of Ranvier Maintenance and Myelinated Axon Function.

Authors:  Anna M Taylor; Julia Saifetiarova; Manzoor A Bhat
Journal:  Front Cell Neurosci       Date:  2017-02-03       Impact factor: 5.505

8.  Antibodies against peripheral nerve antigens in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Luis Querol; Ana M Siles; Roser Alba-Rovira; Agustín Jáuregui; Jérôme Devaux; Catherine Faivre-Sarrailh; Josefa Araque; Ricard Rojas-Garcia; Jordi Diaz-Manera; Elena Cortés-Vicente; Gisela Nogales-Gadea; Miquel Navas-Madroñal; Eduard Gallardo; Isabel Illa
Journal:  Sci Rep       Date:  2017-10-31       Impact factor: 4.379

9.  Rituximab in treatment-resistant CIDP with antibodies against paranodal proteins.

Authors:  Luis Querol; Ricard Rojas-García; Jordi Diaz-Manera; Joseba Barcena; Julio Pardo; Angel Ortega-Moreno; Maria Jose Sedano; Laia Seró-Ballesteros; Alejandra Carvajal; Nicolau Ortiz; Eduard Gallardo; Isabel Illa
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2015-09-03

Review 10.  Neuro-glial interactions at the nodes of Ranvier: implication in health and diseases.

Authors:  Catherine Faivre-Sarrailh; Jérôme J Devaux
Journal:  Front Cell Neurosci       Date:  2013-10-29       Impact factor: 5.505

View more
  21 in total

1.  Accumulation of Neurofascin at Nodes of Ranvier Is Regulated by a Paranodal Switch.

Authors:  Yanqing Zhang; Stephanie Yuen; Elior Peles; James L Salzer
Journal:  J Neurosci       Date:  2020-06-17       Impact factor: 6.167

Review 2.  Pathogenic autoantibodies in multiple sclerosis - from a simple idea to a complex concept.

Authors:  Romana Höftberger; Hans Lassmann; Thomas Berger; Markus Reindl
Journal:  Nat Rev Neurol       Date:  2022-08-15       Impact factor: 44.711

Review 3.  Guillain-Barré syndrome: expanding the concept of molecular mimicry.

Authors:  Jon D Laman; Ruth Huizinga; Geert-Jan Boons; Bart C Jacobs
Journal:  Trends Immunol       Date:  2022-03-04       Impact factor: 19.709

Review 4.  Distinguish CIDP with autoantibody from that without autoantibody: pathogenesis, histopathology, and clinical features.

Authors:  Lisha Tang; Qianyi Huang; Zhen Qin; Xiangqi Tang
Journal:  J Neurol       Date:  2020-04-07       Impact factor: 4.849

Review 5.  The immune response and aging in chronic inflammatory demyelinating polyradiculoneuropathy.

Authors:  Kathleen M Hagen; Shalina S Ousman
Journal:  J Neuroinflammation       Date:  2021-03-22       Impact factor: 8.322

Review 6.  Evolution of Anti-B Cell Therapeutics in Autoimmune Neurological Diseases.

Authors:  Panos Stathopoulos; Marinos C Dalakas
Journal:  Neurotherapeutics       Date:  2022-02-18       Impact factor: 6.088

Review 7.  Anti-Neurofascin 155 Antibody-Positive Chronic Inflammatory Demyelinating Polyneuropathy/Combined Central and Peripheral Demyelination: Strategies for Diagnosis and Treatment Based on the Disease Mechanism.

Authors:  Jun-Ichi Kira
Journal:  Front Neurol       Date:  2021-06-10       Impact factor: 4.003

8.  Antibodies to neurofascin, contactin-1, and contactin-associated protein 1 in CIDP: Clinical relevance of IgG isotype.

Authors:  Andrea Cortese; Raffaella Lombardi; Chiara Briani; Ilaria Callegari; Luana Benedetti; Fiore Manganelli; Marco Luigetti; Sergio Ferrari; Angelo M Clerici; Girolama Alessandra Marfia; Andrea Rigamonti; Marinella Carpo; Raffaella Fazio; Massimo Corbo; Anna Mazzeo; Fabio Giannini; Giuseppe Cosentino; Elisabetta Zardini; Riccardo Currò; Matteo Gastaldi; Elisa Vegezzi; Enrico Alfonsi; Angela Berardinelli; Ludivine Kouton; Constance Manso; Claudia Giannotta; Pietro Doneddu; Patrizia Dacci; Laura Piccolo; Marta Ruiz; Alessandro Salvalaggio; Chiara De Michelis; Emanuele Spina; Antonietta Topa; Giulia Bisogni; Angela Romano; Sara Mariotto; Giorgia Mataluni; Federica Cerri; Claudia Stancanelli; Mario Sabatelli; Angelo Schenone; Enrico Marchioni; Giuseppe Lauria; Eduardo Nobile-Orazio; Jérôme Devaux; Diego Franciotta
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2019-11-21

9.  Antiparanodal antibodies and IgG subclasses in acute autoimmune neuropathy.

Authors:  Luise Appeltshauser; Anna-Michelle Brunder; Annika Heinius; Peter Körtvélyessy; Klaus-Peter Wandinger; Ralf Junker; Carmen Villmann; Claudia Sommer; Frank Leypoldt; Kathrin Doppler
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2020-07-24

Review 10.  Complement in neurological disorders and emerging complement-targeted therapeutics.

Authors:  Marinos C Dalakas; Harry Alexopoulos; Peter J Spaeth
Journal:  Nat Rev Neurol       Date:  2020-10-01       Impact factor: 42.937

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.